Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.65 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4841984 | 0.98 | GFER (0.67) | GFERCYP19A1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL62020 | 0.85 | CYP17A1 (0.87) | GFERCYP19A1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL8164156 | 0.84 | GFER (1.00) | GFERCYP19A1CYP3A4LOXL2MAOB | |
| SCHEMBL187043 | 0.84 | GFER (1.00) | GFERCYP19A1CYP3A4LOXL2MAOB | |
| SCHEMBL3482833 | 0.84 | GFER (1.00) | GFERCYP19A1CYP3A4LOXL2MAOB | |
| SCHEMBL151822 | 0.84 | LOXL2 (0.68) | CYP3A4CYP17A1CYP11B1LOXL2ALDH1A1 | |
| Water SCHEMBL31124597 | 0.81 | LOXL2 (0.65) | CYP3A4CYP17A1CYP11B1LOXL2ALDH1A1 | |
| Water SCHEMBL31124596 | 0.81 | LOXL2 (0.65) | CYP3A4CYP17A1CYP11B1LOXL2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8653872 | 0.81 | GFER (0.93) | GFERCYP19A1CYP3A4LOXL2MAOB | |
| Ammonia Solution, Strong SCHEMBL9306930 | 0.81 | LOXL2 (0.65) | CYP3A4CYP17A1CYP11B1LOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300155-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3354646-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2985281-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9796698-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2017-03-30 | — | — | US | disclosed |
| US-9550766-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2016-04-28 | — | — | US | disclosed |
| EP-2985281-A2 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Celgene Corporation (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9227954-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007056016-A2 | BISAMIDE CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
| EP-0638553-A1 | Carboxylic acid amides having a terminal carboxylic acid group as aggregation inhibiting drugs | Dr. Karl Thomae GmbH (DE) | 1995-02-15 | — | — | EP | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | GFER 3825/4885CYP19A1 462/4885CYP3A4 2878/4885 |
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | GFER 4507/4885CYP19A1 738/4885CYP3A4 102/4885 |
| US-10300155-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | GFER 3408/4885CYP19A1 4872/4885CYP3A4 4715/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | GFER 3825/4885CYP19A1 462/4885CYP3A4 2878/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | GFER 4398/4885CYP19A1 144/4885CYP3A4 2456/4885 |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | GFER 4507/4885CYP19A1 738/4885CYP3A4 102/4885 |
| US-20170189566-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | GFER 3408/4885CYP19A1 4872/4885CYP3A4 4715/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | GFER 3825/4885CYP19A1 462/4885CYP3A4 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.